A New Light: The BCI Implant Restoring Vision to Millions with AMD

ALAMEDA, CA & PARIS, FRANCE – July 22, 2026 – For the more than five million people globally succumbing to the slow, irreversible darkness of geographic atrophy (GA), the central part of their world has been fading to black. This advanced form of age-related macular degeneration (AMD) robs individuals of their central vision, erasing faces, words on a page, and the very independence that comes with sight. For decades, the diagnosis was a prelude to blindness with no available treatment. That reality has just been fundamentally altered.

Science Corporation, a neural engineering firm with ambitions that stretch to the edge of biology, has announced the European commercial launch of its PRIMA system. This is not another drug that merely slows the disease's march; it is a brain-computer interface (BCI) designed to restore functional vision. Having secured a CE mark, the device is now authorized for sale across 30 European nations, heralding a new era for patients and a pivotal moment for the entire BCI industry. The first commercial implant is expected to happen soon in Germany, marking the transition of this technology from clinical trial to clinical reality.

“For decades, losing central vision to this disease meant losing the ability to read, recognize faces, and ultimately losing independence. There was no viable treatment. Now there is,” said Max Hodak, CEO and co-founder of Science. The company's achievement represents the first BCI ever to receive a CE mark for restoring form vision—the ability to discern letters and words—a milestone that shifts the technology from the realm of experimental science to a tangible therapeutic tool.

A Landmark for Patients and Neural Engineering

The PRIMA system is a testament to the sophisticated integration of hardware and biology. It consists of a tiny, ultra-thin photovoltaic implant, surgically placed beneath the atrophied macula at the center of the retina. This implant works in tandem with specialized glasses worn by the patient. The glasses house a camera that captures the visual scene and a projector that beams near-infrared light onto the subretinal chip. The chip converts this light into electrical stimulation, activating the remaining ganglion cells in the retina, which then transmit the visual signal to the brain. The brain learns to interpret these new signals as a coherent image. A built-in “zoom-in” feature even allows patients to magnify text, directly addressing one of the most debilitating aspects of central vision loss.

The clinical data, published in the prestigious New England Journal of Medicine, underpins the company's claims with compelling evidence. In a multi-center trial involving 38 patients, the results were transformative. On average, patients experienced an improvement equivalent to reading more than five additional lines on an ETDRS eye chart. An astounding 84% of patients reported the ability to read letters, numbers, and words, effectively restoring the functional central vision they had lost. The safety profile was also strong, with the implant being placed successfully without degrading the patients' remaining peripheral vision.

“It has been demonstrated in clinical trials that with PRIMA, we can restore functional central vision in patients blinded by geographic atrophy,” affirmed Dr. Frank Holz, the lead investigator of the clinical trial and Chair of the Department of Ophthalmology at the University Hospital of Bonn, Germany. “These patients, who had lost their central vision completely, have had it restored.”

Navigating a Fractured Treatment Landscape

Science Corporation's claim that PRIMA is the “only treatment to restore functional central vision” is not marketing hyperbole; it is a critical distinction in a complex and evolving therapeutic landscape. This is especially true in Europe. While the United States recently saw the FDA approve two new drugs—Syfovre and Izervay—for geographic atrophy, these treatments function very differently. Administered via regular eye injections, they work to slow the progression of retinal cell death. They do not, however, repair damage or restore vision that has already been lost.

Significantly, neither of these drugs has been approved for use in Europe. The European Medicines Agency's (EMA) advisory committee concluded that the modest slowing of lesion growth observed in trials did not translate into a meaningful functional benefit for patients, leading the manufacturers to withdraw their applications. This regulatory divergence leaves European GA patients without any approved pharmaceutical options, making PRIMA's arrival not just timely, but singularly essential.

PRIMA enters the European market not as an alternative, but as the sole therapeutic option capable of turning back the clock on vision loss. This unique positioning provides the company with a powerful narrative, but it also places immense pressure on the technology to deliver consistent, life-altering results in a real-world setting, far beyond the controlled environment of a clinical trial.

From CE Mark to Clinic: The Gauntlet of Market Access

Achieving the CE mark is a monumental regulatory victory, but it is only the first step on the arduous path to widespread patient access. The true challenge for Science Corporation now lies in navigating the labyrinthine reimbursement systems of 30 different European countries. A CE mark grants the right to sell a device, but it does not compel national health systems to pay for it.

With nearly half a billion dollars in capital raised—much of it earmarked for commercialization—the neural engineering firm is well-funded but faces a daunting task. Each country has its own health technology assessment (HTA) body, such as Germany's IQWiG or France's HAS, which will scrutinize PRIMA's clinical data, long-term efficacy, and, most importantly, its cost-effectiveness. Leaders at the company will need to build a compelling economic case demonstrating that the high upfront cost of the device and surgery is justified by long-term benefits, such as reduced caregiver dependency and improved quality of life for patients.

“Securing reimbursement is a country-by-country, street-by-street fight,” noted one health economics consultant who wished to remain anonymous. “You have to prove not just that it works, but that it’s worth the price to a system managing a thousand other priorities.”

Beyond reimbursement, the operational rollout presents its own set of hurdles. The subretinal surgical procedure is delicate and will require specialized training for ophthalmic surgeons. Establishing a network of certified clinical sites equipped to perform the surgery and manage patient follow-up will be a significant logistical undertaking. Patient selection will also be critical to ensure that those most likely to benefit are prioritized, managing expectations and building a track record of success from the outset.

Science Corporation is concurrently pursuing market entry in the United States, where PRIMA has received Breakthrough Device and Humanitarian Use Device designations from the FDA. Success in Europe could provide a powerful tailwind for its efforts across the Atlantic, offering a robust portfolio of real-world evidence and patient outcomes. The company's journey is no longer just about neural engineering; it is about mastering the intricate business of global healthcare delivery.